Effects of Magnesium L-Threonate on Sleep, Recovery, and Athletic Performance in Collegiate Athletes
NCT ID: NCT07015047
Last Updated: 2025-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
100 participants
INTERVENTIONAL
2025-10-01
2026-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, healthy UCLA varsity athletes aged 18 to 35 will be randomly assigned to take either magnesium L-threonate or a placebo each evening for 4 weeks. They will wear a WHOOP strap to track sleep, recovery, and heart rate data. Performance tests including jump height, grip strength, and reaction time will be completed before and after the 4-week period.
This study will help researchers determine if this supplement can support recovery and training in athletes and whether wearable technology can help monitor these changes in real time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes
NCT05032729
Effects of Caffeine and L-Theanine on Physical and Cognitive Performance in Trained Athletes
NCT07268573
Nutrients to Enhance Sleep Quality and Quantity
NCT03288077
Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels
NCT06979648
The Effects of 10 Days of Extreme Endurance on Performance
NCT03337737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 100 UCLA varsity athletes aged 18-35 will be randomized in a 1:1 ratio to receive 1 gram of MgT or placebo nightly for 4 weeks. Participants will wear a WHOOP strap to continuously monitor deep sleep, REM sleep, heart rate variability, resting heart rate, and recovery score. Daily surveys will track subjective sleep quality, recovery, and for female athletes, menstrual phase and symptoms. Performance outcomes including countermovement jump height, handgrip strength, and light-based reaction time will be measured before and after the intervention.
Primary outcomes include objective changes in sleep stages and HRV. Secondary outcomes include changes in physical performance and subjective recovery. This study will provide insight into whether brain-targeted magnesium supplementation can enhance recovery and performance in an athletic population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Magnesium L-Threonate
Participants assigned to this arm will take 1 gram of magnesium L-threonate (Magtein) in capsule form each evening for 4 weeks. They will wear a WHOOP strap continuously to collect sleep and recovery metrics and complete baseline/follow-up performance testing.
Magnesium L-Threonate
Participants in this arm will take 1 gram of magnesium L-threonate (Magtein), provided in capsule form, once daily in the evening for 4 weeks. This supplement is known for its ability to cross the blood-brain barrier and may enhance sleep architecture, autonomic recovery, and cognitive function.
Placebo
Participants assigned to this arm will take an identical-looking placebo capsule each evening for 4 weeks. They will wear a WHOOP strap continuously to collect sleep and recovery metrics and complete baseline/follow-up performance testing.
Placebo
Identical-looking inert capsule taken nightly for 4 weeks. Used as a comparator to magnesium L-threonate to assess changes in sleep, recovery, and performance metrics.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium L-Threonate
Participants in this arm will take 1 gram of magnesium L-threonate (Magtein), provided in capsule form, once daily in the evening for 4 weeks. This supplement is known for its ability to cross the blood-brain barrier and may enhance sleep architecture, autonomic recovery, and cognitive function.
Placebo
Identical-looking inert capsule taken nightly for 4 weeks. Used as a comparator to magnesium L-threonate to assess changes in sleep, recovery, and performance metrics.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current UCLA varsity athlete (any sport)
* Actively training or competing during the study period
* Willing to wear a WHOOP strap continuously for 4 weeks
* Willing to ingest a nightly capsule for 4 weeks
* Able to provide informed consent and comply with study procedures
Exclusion Criteria
* Use of prescription or over-the-counter sleep medications
* Diagnosed sleep disorder (e.g., insomnia, sleep apnea)
* Major medical condition limiting training or participation
* Pregnancy or breastfeeding
* Known history of chronic kidney or liver disease
* Allergy or intolerance to magnesium
* Inability to comply with study procedures (e.g., wearing WHOOP or completing surveys)
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeremy Swisher, MD
Health Sciences Assistant Clinical Professor, Department of Orthopaedic Surgery - Sports Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-25-1201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.